Invion Ltd. · ASX:IVX

Invion — Investor Presentation (July 2015)

35 slides from Invion's investor presentation, July 2015

  1. Slide 1: Invion Limited (ASX:IVX) Investor Presentation

    Invion Limited (ASX:IVX) Clinical-stage life sciences company targeting chronic inflammation Investor Presentation July | 2015

  2. Slide 2: Disclaimer

    Disclaimer • The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited ACN 094 730 417 (Company). In prepa

  3. Slide 3: Assets in development

    Assets in development Respiratory 1. INV102 (nadolol): is a beta blocker (beta adrenergic biased ligand) currently used to treat high blood pressure, coronary chest pain (angina) and migraine, being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). Oral INV102 is being

  4. Slide 4: Spectrum of airway disease and opportunities

    Spectrum of airway disease and opportunities Global market size: $34B $2.4B $1.2B Exercise Mild Moderate Severe Chronic Smoker’s Cys5c Induced Asthma Asthma Asthma Bronchi5s Cough Fibrosis Asthma INV104 (zafirlukast) INV102 (nadolol) Monotherapy + combinations Monotherapy + combinations 4

  5. Slide 5: Targeting chronic inflammatory airway disease

    Targeting chronic inflammatory airway disease Oral INV102 (nadolol)

  6. Slide 6: Treating the airway: background and rationale

    Treating the airway: background and rationale > Existing drugs do an excellent job in opening constricted airways: bronchodilators include β-adrenergic and anti-muscarinic drug classes > Existing drugs do an excellent job in decreasing inflammatory cells in the airway: inhaled corticosteroid (ICS) a

  7. Slide 7: The vicious cycle of chronic inflammatory airway disease

    The “vicious cycle” of chronic inflammatory airway disease Inflammation from: - cigarette smoke Increased - chronic infection (C.F.) IL-8 and - allergen, O3 (asthma) beta- + arrestin pathway activity Increased goblet cell Changes in production/ basal cell loss of populations ciliated epithelial cell

  8. Slide 8: Nadolol has unique properties that could treat airway disease

    Nadolol has unique properties that could treat airway disease > In cell experiments, INV102 (nadolol): > Blocks the β-arrestin pathway on airway epithelial cell β2 receptors (Lefkowitz) > In animal experiments, nadolol: > Blocks (prevents) or reduces (treats) the increase in goblet cells caused by i

  9. Slide 9: Nadolol could reverse the vicious cycle of airway inflammation

    Nadolol could reverse the “vicious cycle” of airway inflammation Shown in clinical trial Nadolol DECREASED + IL-8 and beta- arrestin pathway activity DECREASED goblet cell Restoration production/ of ciliated loss of epithelial ciliated Mucous metaplasia found in cells epithelial COPD, asthma and CF

  10. Slide 10: Oral nadolol program: progress and active clinical trials and results

    Oral nadolol program: progress and active clinical trials and results Clinical benefits ü the only drug targeted to address the unmet medical need of mucous metaplasia in the airway ü targeted as an add-on to existing therapies to make them safer and more effective by reducing mucous production ü

  11. Slide 11: Oral nadolol: phase II smoking cessation study reporting Q315

    Oral nadolol: 155 patient phase II smoking cessation study reporting Q315. Leveraging the data: upcoming analysis and reporting Third quarter planned analyses and reporting Fourth Quarter Biomarkers Smoking cessation Combined data > Report on effects of nadolol vs placebo > Report on smoking cessati

  12. Slide 12: Oral nadolol: positive endpoint data leads to

    Oral nadolol: 155 patient phase II smoking cessation study reporting Q315. Positive endpoint data Leads to Oral nadolol program: Smoking Safety Biomarkers end of Phase II meeting cessation with FDA / Phase III > Safety of > Report on > Report on Inhaled nadolol program: > titration doses No need for

  13. Slide 13: Nadolol franchise: progressively de-risked

    Nadolol franchise: progressively de-risked oral nadolol inhaled nadolol Data from current Inhaled nadolol is phase II trials in asthma Safety and targeted to treat COPD, biomarker data asthma and cystic and smoking cessation from oral phase II fibrosis. will support the programs will development of

  14. Slide 14: Respiratory therapeutics: inhaled program

    Respiratory therapeutics: inhaled program INV102 (nadolol) in asthma, COPD & cystic fibrosis

  15. Slide 15: Inhaled nadolol program: progress and clinical development strategy

    Inhaled nadolol program: progress and clinical development strategy Clinical benefits ü once daily dosing directly to the site of injury at 1/100 of the oral dose to mitigate systemic side effects ü targeted for long term use in COPD, severe asthma and cystic fibrosis as an add-on to existing ther

  16. Slide 16: Inhaled INV102: program status

    Inhaled INV102: program status > Collaboration with 3M Drug Delivery systems > Target outcome: proprietary formulation and device using 3M’s proprietary pressurised metered dose inhalation (pMDI) technology > Collaboration encompasses manufacture for toxicology and phase I studies > Formulation and

  17. Slide 17: Nadolol franchise: market size, relevance and interconnectedness

    Nadolol franchise: market size, relevance and interconnectedness Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow. 17

  18. Slide 18: INV104 (zafirlukast)

    INV104 (zafirlukast) Target: a novel inhaled non-steroidal anti-inflammatory treatment for asthma

  19. Slide 19: Target: an inhaled reformulation of a successful oral therapeutic for asthma

    Target: an inhaled reformulation of a successful oral therapeutic for asthma INV104 (zafirlukast): > Leukotriene-receptor antagonist (LTRA) or “anti-leukotriene” that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs > Approved worldwide as an oral tablet for

  20. Slide 20: Inhaled zafirlukast an anti-leukotriene: background and rationale

    Inhaled zafirlukast an anti-leukotriene: background and rationale Defined safety Defined CMC profile Airway & nasal Full toxicology 200mcg demonstrated secretions are rich in package completed 12 hour protection LTC4, D4 and E4 Excellent flow using CFC-based Single and multiple from allergen. Once (

  21. Slide 21: FDA pre-IND established framework for reformulation of zafirlukast

    FDA pre-IND established framework for reformulation of zafirlukast Agreement reached with FDA on: > chemistry manufacturing and controls (GMP) > active pharmaceutical ingredient (API) with drug master file (DMF) > formulation: dry powder inhaler (DPI) approved for development > toxicology and bioana

  22. Slide 22: Inhaled Product Rationale

    Inhaled Product Rationale Oral Inhaled Forms Form Risk of neuropsychiatric/suicide ideation events? Risk of liver toxicity ? Greater efficacy due to higher airway concentrations Potential for once a day dosing ? Singulair Potential for expanded EIB claims ? Prevention Only Rapid onset-of-action for

  23. Slide 23: Hovione CMC collaboration mitigates major risk of inhaled zafirlukast development

    Hovione CMC collaboration mitigates major risk of inhaled zafirlukast development Formulation & device partner, Hovione > Invion will collaborate with Hovione to develop the proprietary novel technology – a dry powder formulation of zafirlukast and the accompanying inhalational delivery device > und

  24. Slide 24: About Hovione and the XCaps inhaler

    About Hovione and the XCaps inhaler > International company with over 50 years’ experience in the development and compliant manufacture of active pharmaceutical ingredients and drug product intermediates > With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses o

  25. Slide 25: Expected placement of inhaled zafirlukast in treatment regimes

    Expected placement of inhaled zafirlukast in treatment regimes > As many as 334 million people have asthma which occurs in people of all ages. Wheeze is the most common symptom and the burden of disability is high. > In 2007 the U.S. spent over $56 billion on asthma care, of which nearly $27 billion

  26. Slide 26: Inhaled zafirlukast program: progress and clinical development strategy

    Inhaled zafirlukast program: progress and clinical development strategy Clinical benefits ü FDA approved as an oral asthma therapy ü Proof of concept previously conducted using inhaled drug ü Non-steroidal ü Higher local concentrations without systemic exposure (decreased risk of generic duplica

  27. Slide 27: Targeting chronic inflammation caused by autoimmune disease

    Targeting chronic inflammation caused by autoimmune disease INV103 (ala-Cpn10)

  28. Slide 28: INV103 (ala-Cpn10): background and rationale

    INV103 (ala-Cpn10): background and rationale > Minimally modified form of naturally occurring protein > Maintains heptameric structure and function > Intracellular function: prevent protein misfolding > Extracellular function: Cpn10 proposed as a founding member of the Resolution Associated Molecula

  29. Slide 29: INV103: Mechanism of action

    INV103: Mechanism of action HSP10 References: Resolution-associated molecular patterns (RAMPs) in the acute inflammatory response. Inflammation initiates the over-expression and release of RAMPs, such as Cpn10 (Hsp10). These help limit and resolve the inflammatory responses via a variety of direct a

  30. Slide 30: Ala-Cpn10 deliverables

    Ala-Cpn10 deliverables > Completion of dosing of all 4 cohorts > Safety, pharmacokinetics and anti-drug antibodies > Biomarkers of SLE activity including: > Serum IL-6, TNFα, ICAM-1, MCP-1, VCAM-1, > Urinary protein and MCP-1 > Focus on Peripheral Blood Monocytic Cells (PBMC) stimulated by LPS to me

  31. Slide 31: Pipeline

    Pipeline Research Formulation Phase I Phase II ………….. ………….. ………….. Next milestone development and clinical feasibility Oral INV102 (nadolol) Completion of enrolment Asthma NIH funded 2H15, Reporting 2016 Smoking cessation Phase II data 3Q15 Inhaled INV102 (nadolol) Pre-IND status achieved 1Q15 Asth

  32. Slide 32: Program targets: 12-18 months

    Program targets: 12-18 months > Oral nadolol: > advanced into Phase III as an adjunct to smoking cessation in patients with chronic cough and/or chronic bronchitis > IP based on combination of nadolol safety and efficacy with diagnostics from smoking cessation study > Inhaled nadolol: > Proprietary

  33. Slide 33: Board and Management with proven track record

    Board and Management with proven track record > Chairman of Board of Directors, Mr Brett Heading > Senior partner of law firm McCullough Robertson, 27 years as a company director. Former Chairman, ChemGenex Pharmaceuticals (sold to Cephalon $230M); former Director, Peplin Biotech Limited. > Managing

  34. Slide 34: Corporate snapshot

    Corporate snapshot Sector Life Sciences (Biotechnology) Principal activities Clinical-stage pharmaceutical drug development Pipeline 3 drug assets, multiple clinical and pre-clinical programs Operations Australia & USA ASX code IVX Share price (17-Jul-15) $0.028 (2.8 cents) Shares on issue ~822 M Op

  35. Slide 35: Dr Greg Collier, Managing Director and CEO, Invion Limited

    Dr Greg Collier Managing Director and CEO Invion Limited c/- McCullough Robertson Lawyers, Level 11, 66 Eagle Street Brisbane, QLD, 4000 Australia P: +61 7 3295 0500 E: greg.collier@inviongroup.com W: www.inviongroup.com Investor Presentation July | 2015

Invion — Investor Presentation (July 2015) on 6ix